Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
2,161 to 2,180 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Crosstalk of Histone and RNA Modifications Identified a Stromal-Activated Subtype with Poor Survival and Resistance to Immunotherapy in Gastric Cancer. | Front Pharmacol | 2022 | 35600848 | PubTator, text mining | PubMed |
| [Comprehensive Analysis of the Relationship between m6A Methylation Patterns and Immune Microenvironment in Lung Adenocarcinoma]. | Zhongguo Fei Ai Za Zhi | 2022 | 35599007 | PubTator, text mining | PubMed |
| Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-κB/IL-6 signaling pathway. | Cell Mol Life Sci | 2022 | 35598196 | PubTator, text mining | PubMed |
| Upregulation of METTL14 contributes to trophoblast dysfunction by elevating FOXO3a expression in an m6A-dependent manner. | Placenta | 2022 | 35597169 | PubTator, text mining | PubMed |
| METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m6A-dependent manner. | Cell Mol Biol Lett | 2022 | 35596159 | PubTator, text mining | PubMed |
| m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling. | Cell Death Dis | 2022 | 35595748 | PubTator, text mining | PubMed |
| M5C-Related lncRNA Predicts Lung Adenocarcinoma and Tumor Microenvironment Remodeling: Computational Biology and Basic Science. | Front Cell Dev Biol | 2022 | 35592248 | PubTator, text mining | PubMed |
| The importance of N6-methyladenosine modification in tumor immunity and immunotherapy. | Exp Hematol Oncol | 2022 | 35590394 | PubTator, text mining | PubMed |
| The potential role of N7-methylguanosine (m7G) in cancer. | J Hematol Oncol | 2022 | 35590385 | PubTator, text mining | PubMed |
| Four Types of RNA Modification Writer-Related lncRNAs Are Effective Predictors of Prognosis and Immunotherapy Response in Serous Ovarian Carcinoma. | Front Immunol | 2022 | 35585970 | PubTator, text mining | PubMed |
| METTL3-mediated macrophage exosomal NEAT1 contributes to hepatic fibrosis progression through Sp1/TGF-β1/Smad signaling pathway. | Cell Death Discov | 2022 | 35585044 | PubTator, text mining | PubMed |
| DDX5/METTL3-METTL14/YTHDF2 Axis Regulates Replication of Influenza A Virus. | Microbiol Spectr | 2022 | 35583334 | PubTator, text mining | PubMed |
| [Lipopolysaccharide induces inflammation and up-regulates the expression of methyltransferase-like 3 (METTL3) and METTL14 in human and mouse intestinal epithelial cells]. | Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi | 2022 | 35583059 | PubTator, text mining | PubMed |
| YTHDF2 promotes temozolomide resistance in glioblastoma by activation of the Akt and NF-κB signalling pathways via inhibiting EPHB3 and TNFAIP3. | Clin Transl Immunology | 2022 | 35582627 | PubTator, text mining | PubMed |
| Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma. | Cancer Drug Resist | 2022 | 35582537 | PubTator, text mining | PubMed |
| Structural and functional specificity of H3K36 methylation. | Epigenetics Chromatin | 2022 | 35581654 | PubTator, text mining | PubMed |
| ERBB3 methylation and immune infiltration in tumor microenvironment of cervical cancer. | Sci Rep | 2022 | 35581263 | PubTator, text mining | PubMed |
| Deep learning modeling m6A deposition reveals the importance of downstream cis-element sequences. | Nat Commun | 2022 | 35581216 | PubTator, text mining | PubMed |
| Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m6A demethylation of EIF4EBP1 and MLST8 mRNA. | Cell Oncol (Dordr) | 2022 | 35579750 | PubTator, text mining | PubMed |
| Nanopore-Based Detection of Viral RNA Modifications. | mBio | 2022 | 35579392 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=109